

**Sublingual Tablet Immunotherapy for the Management of Patients with AR: Applying Evidence to Evolving
Clinical Practice
Tweeterial References**

Tweet 5

Saporta D. Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice. *BioMed Research International*. 2016;2016: 9323804. <https://doi.org/10.1155/2016/9323804>

Tweet 6

Lin SY, et al. Rockville, MD: Agency for Healthcare Research and Quality; 2013. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-EHC061-EF.

Wise SK, Lin SY, Toskala E, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. *Int Forum Allergy Rhinol*. 2018;8(2):108-352. <https://doi.org/10.1002/alr.22073>

Tweet 7

US Food and Drug Administration. Allergen extract SLIT tablets. FDA website. Accessed April 28, 2021. <https://www.fda.gov/vaccines-blood-biologics/allergenics/allergen-extract-sublingual-tablets>

ALK, Inc. ALK announces that ITULATEK sublingual allergy immunotherapy (SLIT)-tablet for the treatment of tree pollen allergy is now available in Canada. ALK website. October 05, 2020. Accessed April 28, 2021. <https://www.newswire.ca/news-releases/alk-announces-that-itulatek-tm-sublingual-allergy-immunotherapy-slit-tablet-for-the-treatment-of-tree-pollen-allergy-is-now-available-in-canada-860782609.html>

Tweet 9

Odactra PI. Ragwitek PI. Grastek PI. Oralair PI.

Tweet 10

Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. *J Allergy Clin Immunol*. 2012;129(3):717-725. <https://doi.org/10.1016/j.jaci.2011.12.973>

Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. *Ann Allergy Asthma Immunol*. 2014;112(2):146-153. <https://doi.org/10.1016/j.anai.2013.11.018>

Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. *J Allergy Clin Immunol*. 2011;127(1):64-71 <https://doi.org/10.1016/j.jaci.2010.11.034>

Tweet 11

Didier A, Malling HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. *Clin Transl Allergy*. 2015;5:12. <https://dx.doi.org/10.1186%2Fs13601-015-0057-8>

Tweet 12

Nolte H, Hebert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. *Ann Allergy Asthma Immunol*. 2013;110(6):450-456. <https://doi.org/10.1016/j.anai.2013.03.013>

Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. *J Allergy Clin Immunol*. 2013 May;131(5):1342-9. <https://doi.org/10.1016/j.jaci.2013.03.019>

Tweet 13

Nolte H, Bernstein DI, Nelson HS, et al. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. *J Allergy Clin Immunol Pract*. 2020;8(7):2322-2331. <https://doi.org/10.1016/j.jaip.2020.03.041>

Tweet 14

Maloney J, Bernstein DI, Herbert J, et al. The Efficacy and Safety Of The Short Ragweed Sublingual Immunotherapy Tablet MK-3641 Is Similar In Asthmatic and Nonasthmatic Subjects Treated For Allergic Rhinitis With/Without Conjunctivitis (AR/C). *J Allergy Clin Immunol*. 2014;AB218 <https://doi.org/10.1016/j.jaci.2013.12.778>

Tweet 15

Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. *J Allergy Clin Immunol*. 2016;137(2):444-451. <https://doi.org/10.1016/j.jaci.2015.06.036>

Tweet 16

Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. *J Allergy Clin Immunol*. 2015 Jun;135(6):1494-501. <https://doi.org/10.1016/j.jaci.2014.12.1911>

Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2016;138(6):1631-1638. <https://doi.org/10.1016/j.jaci.2016.06.044>

Tweet 17

Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. *J Allergy Clin Immunol*. 2015 Jun;135(6):1494-501. <https://doi.org/10.1016/j.jaci.2014.12.1911>

Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2016;138(6):1631-1638. <https://doi.org/10.1016/j.jaci.2016.06.044>

Tweet 18

Biedermann T, Kuna P, Panzner P, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. *J Allergy Clin Immunol*. 2019;143(3):1058-1066. <https://doi.org/10.1016/j.jaci.2018.12.1001>

Tweet 19

Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? *J Allergy Clin Immunol*. 2016;137(2):339-349. <https://doi.org/10.1016/j.jaci.2015.12.1298>

Trebuchon F, et al. *Clin and Trans All*. 2015;4(15).

Tweet 20

Field K, Blaiss MS. Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations? *Curr All Asthma Reps*. 2020;20(9):1-8. <https://doi.org/10.1007/s11882-020-00934-4>

Glossary

AEs, adverse events

AHRQ, Agency for Healthcare Research and Quality

AIT, Allergy Immunotherapy

Approx, approximately

ARC, allergic rhinoconjunctivitis

DMS, daily medication score

DSS, daily symptom score

FDA, Food and Drug Administration

HDM, house dust mite

IT, Immunotherapy

Opps, opportunities

PED, pediatric

Pts, patients

SABA, short-acting beta agonists

SCIT, Subcutaneous Immunotherapy

SLIT, Sublingual Immunotherapy

SQ, standardized quality

TCS, total combined score

Tx, treatment

US, United States

Yrs, years

